Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Over the past decade, patients admitted to addiction treatment programs have reported increasing rates of concurrent opioid and benzodiazepine (BZD) use. This drug combination places individuals at high risk for accidental overdose. Little is known about reasons for BZD use among individuals seeking treatment for opioid use disorders. Methods We surveyed consecutive persons initiating inpatient opioid detoxification and identified 176 out of 438 who reported BZD use in the past 30 days and/or had a positive toxicology. Results Forty percent of persons surveyed used a BZD in the month prior to admission, and 25% of these met criteria for BZD dependence (DSM IV). BZD users averaged 32.0 years of age, 63.6% were male, 85.2% used heroin, and reported, on average, 13.3 (± 11.2) days of BZD use during the past month. Alprazolam (Xanax) was the most commonly used BZD (52%), and buying it on the street the most common source (48%). The most commonly reported reason for BZD use was ‘to manage anxiety’ (42.6%), followed by ‘to get or enhance a high’ (27.7%), ‘to help with sleep’ (11.4%), and ‘to decrease opioid withdrawal’ (10.2%). The most common reason for BZD use was significantly associated (p < .001) with most likely source of BZDs, with persons who got their BZDs from a prescriber (23%) more likely to report BZD anxiety as their primary reason for use, while persons who bought BZDs on “the street” (48%) had the highest likelihood of reporting using BZD to get or enhance a high. Participants using BZDs most commonly for anxiety did not endorse lower anxiety than those using BZDs for other reasons. Conclusions Two in five persons seeking detoxification for an opioid use disorder used a BZD in the prior month. Anxiety was the most common reason patients reported using a benzodiazepine, but they also reported using BZDs to enhance a ‘high’ and manage opioid withdrawal. Evidence-based discussions about the risks of combining BZDs and opioids, and alternatives to BZDs should be a high priority in detoxification settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Löwe, B., Wahl, I., Rose, M., Spitzer, C., Glaesmer, H., Wingenfeld, K., Schneider, A., & Brähler, E. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.019 · Cited by 2,473
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Inciardi, J. A., Surratt, H. L., Cicero, T. J., & Beard, R. A. (2009) · Pain Medicine · doi:10.1111/j.1526-4637.2009.00603.x · Cited by 229
Co-abuse of opiates and benzodiazepines
Rooney, S., Kelly, G., Bamford, L., Sloan, D., & O’Connor, J. J. (1999) · Irish Journal of Medical Science · doi:10.1007/bf02939579 · Cited by 70
Cited by
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479
Park, T. W., Larochelle, M. R., Saitz, R., Wang, N., Bernson, D., & Walley, A. Y. (2020) · Addiction · doi:10.1111/add.14886 · Cited by 78
“Benzodiazepines are efficacious treatments for anxiety and insomnia(19,20), two of the main reasons why patients with opioid use disorder take them(21,22).”
BackgroundBenzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Metadata
- Authors
- Stein, M. D., Kanabar, M., Anderson, B. J., Lembke, A., & Bailey, G. L.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 68
- Pages
- 57-61
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2426516518
- Cited by
- 71
- References
- 6
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.